X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (6916) 6916
Publication (342) 342
Book Review (106) 106
Newsletter (55) 55
Dissertation (25) 25
Book Chapter (15) 15
Conference Proceeding (13) 13
Book / eBook (11) 11
Magazine Article (6) 6
Web Resource (4) 4
Newspaper Article (3) 3
Government Document (1) 1
Streaming Video (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
pharmacology & pharmacy (2602) 2602
animals (2521) 2521
male (2101) 2101
humans (1898) 1898
beta-adrenoceptor (1863) 1863
beta-adrenoceptors (1554) 1554
rats (1374) 1374
index medicus (1040) 1040
female (1036) 1036
adrenergic beta-agonists - pharmacology (720) 720
adrenergic beta-antagonists - pharmacology (657) 657
isoproterenol - pharmacology (653) 653
beta adrenoceptors (603) 603
adult (600) 600
physiology (595) 595
cardiac & cardiovascular systems (581) 581
biochemistry & molecular biology (574) 574
neurosciences (569) 569
dose-response relationship, drug (515) 515
receptors, adrenergic, beta - metabolism (506) 506
in vitro techniques (490) 490
beta-adrenoceptor agonist (478) 478
rats, wistar (472) 472
middle aged (466) 466
rat (448) 448
asthma (440) 440
β-adrenoceptor (436) 436
expression (408) 408
receptors (403) 403
mice (396) 396
research (396) 396
rats, sprague-dawley (389) 389
physiological aspects (388) 388
receptors, adrenergic, beta - drug effects (388) 388
β-adrenoceptors (370) 370
beta-adrenoceptor agonists (364) 364
receptors, adrenergic, beta - physiology (350) 350
heart (342) 342
stimulation (333) 333
propranolol - pharmacology (330) 330
aged (326) 326
propranolol (325) 325
activation (323) 323
receptor (320) 320
cell biology (316) 316
heart rate - drug effects (316) 316
propanolamines - pharmacology (309) 309
hypertension (306) 306
myocardium - metabolism (305) 305
binding (296) 296
catecholamines (283) 283
obesity (282) 282
norepinephrine (279) 279
respiratory system (273) 273
adrenoceptor (267) 267
noradrenaline (264) 264
blood pressure - drug effects (260) 260
endocrinology & metabolism (259) 259
cells (258) 258
isoproterenol (247) 247
adrenoceptors (244) 244
desensitization (244) 244
adrenergic-receptors (243) 243
heart-failure (236) 236
beta-adrenoceptor antagonist (235) 235
medicine, research & experimental (234) 234
time factors (234) 234
analysis (232) 232
beta-adrenoceptor antagonists (232) 232
heart failure (231) 231
relaxation (226) 226
cyclic amp - metabolism (224) 224
urology & nephrology (222) 222
peripheral vascular disease (221) 221
beta-adrenergic receptor (220) 220
myocardial contraction - drug effects (220) 220
camp (219) 219
inhibition (215) 215
adenylate-cyclase (213) 213
smooth-muscle (210) 210
alpha-adrenoceptors (207) 207
down-regulation (206) 206
chemistry, medicinal (204) 204
overactive bladder (204) 204
medicine & public health (203) 203
messenger-rna (203) 203
adrenergic receptors (201) 201
agonist (197) 197
phosphorylation (197) 197
salmeterol (194) 194
responses (193) 193
adrenergic beta-antagonists - therapeutic use (192) 192
heart - drug effects (192) 192
beta-adrenoceptor blockade (191) 191
in-vitro (188) 188
agonists (187) 187
adenylyl cyclases - metabolism (184) 184
guinea pigs (184) 184
cells, cultured (181) 181
salbutamol (179) 179
more...
Library Location Library Location
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (6934) 6934
German (40) 40
French (25) 25
Russian (13) 13
Japanese (12) 12
Spanish (8) 8
Chinese (7) 7
Portuguese (3) 3
Polish (2) 2
Italian (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


CELL METABOLISM, ISSN 1550-4131, 01/2015, Volume 21, Issue 1, pp. 33 - 38
Increasing energy expenditure through activation of endogenous brown adipose tissue (BAT) is a potential approach to treat obesity and diabetes. The class of... 
SELECTIVE BETA-ADRENOCEPTOR AGONIST | THERMOGENESIS | ADRENOCEPTOR AGONIST | ENERGY-EXPENDITURE | COLD-EXPOSURE | METABOLISM | MIRABEGRON | ENDOCRINOLOGY & METABOLISM | DOUBLE-BLIND | FAT | ADULT HUMANS | CELL BIOLOGY
Journal Article
STRUCTURE, ISSN 0969-2126, 06/2008, Volume 16, Issue 6, pp. 897 - 905
The role of cholesterol in eukaryotic membrane protein function has been attributed primarily to an influence on membrane fluidity and curvature. We present... 
CRYSTAL-STRUCTURE | BIOCHEMISTRY & MOLECULAR BIOLOGY | BETA-ADRENOCEPTOR | BENZODIAZEPINE-RECEPTOR | IDENTIFICATION | CELL BIOLOGY | BIOPHYSICS | PROTEIN-COUPLED RECEPTOR | ADENYLYL-CYCLASE | SEQUENCE | MEMBRANE-PROTEINS | AGONIST | LIPIDS
Journal Article
Nature Chemistry, ISSN 1755-4330, 01/2014, Volume 6, Issue 1, pp. 15 - 21
Simulations can provide tremendous insight into the atomistic details of biological mechanisms, but micro-to millisecond timescales are historically only... 
MOLECULAR-DYNAMICS | DATABASE | CRYSTAL-STRUCTURE | DOCKING | EQUILIBRIUM | PROTEIN-COUPLED RECEPTORS | ADRENERGIC-RECEPTOR | ALGORITHMS | BETA ADRENOCEPTOR | CHEMISTRY, MULTIDISCIPLINARY | BETA-ADRENERGIC RECEPTOR | Ligands | Markov Chains | Internet | Receptors, G-Protein-Coupled - metabolism
Journal Article
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, ISSN 0027-8424, 11/2011, Volume 108, Issue 46, pp. 18684 - 18689
A third of marketed drugs act by binding to a G-protein-coupled receptor (GPCR) and either triggering or preventing receptor activation. Although recent... 
MOLECULAR-DYNAMICS | CRYSTAL-STRUCTURE | MULTIDISCIPLINARY SCIENCES | RESOLUTION | ADRENERGIC-RECEPTOR | molecular dynamics | AGONISTS | ligand | ACTIVE STATE | CONFORMATIONS | PROTEIN-COUPLED RECEPTOR | RHODOPSIN | biased signaling | beta-adrenergic | BETA ADRENOCEPTOR | functional selectivity
Journal Article
NATURE COMMUNICATIONS, ISSN 2041-1723, 09/2012, Volume 3
Many drugs that target G-protein-coupled receptors (GPCRs) induce or inhibit their signal transduction with different strengths, which affect their therapeutic... 
STRUCTURAL INSIGHTS | COMPLEX | HETERONUCLEAR CORRELATION SPECTRA | CRYSTAL-STRUCTURE | MULTIDISCIPLINARY SCIENCES | PROTEIN-COUPLED RECEPTORS | BETA ADRENOCEPTOR | SELECTIVITY | AGONISTS | DEPENDENCE | PULSES
Journal Article
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, ISSN 0022-3565, 01/2013, Volume 344, Issue 1, pp. 218 - 230
Vilanterol trifenatate (vilanterol) is a novel, long-acting beta(2)-adrenoceptor (beta(2)-AR) agonist with 24 h activity. In this study, we describe the... 
BETA-ADRENOCEPTOR AGONISTS | BRONCHODILATOR | INDACATEROL | HIGH-AFFINITY | ASTHMA | PHARMACOLOGY & PHARMACY | ADRENERGIC-RECEPTORS | BINDING | SALMETEROL | COPD | BETA-AGONISTS
Journal Article
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, ISSN 1073-449X, 04/2013, Volume 187, Issue 7, pp. 690 - 696
beta(2)-Agonists are effective bronchodilators due primarily to their ability to relax airway smooth muscle (ASM). They exert their effects via their binding... 
COST-EFFECTIVENESS | INHALED BETA-ADRENOCEPTOR AGONIST | DOSE-RESPONSE | PHARMACOLOGICAL CHARACTERIZATION | COMBINATION THERAPY | LONG-ACTING BETA-AGONIST | asthma | OBSTRUCTIVE PULMONARY-DISEASE | beta-agonists | EMERGENCY-DEPARTMENT | RESPIRATORY SYSTEM | pharmacology | 24-H DURATION | guidelines | COPD | CRITICAL CARE MEDICINE
Journal Article
CLINICAL THERAPEUTICS, ISSN 0149-2918, 10/2012, Volume 34, Issue 10, pp. 2144 - 2160
Background: Mirabegron (YM178) is a beta(3)-adrenoceptor agonist for the treatment of overactive bladder (OAB). As part of the clinical development program for... 
BETA-3-ADRENOCEPTOR AGONIST | POTENT | gender | METABOLISM | elderly | YM178 | pharmacokinetics | PHARMACOLOGY & PHARMACY | mirabegron | overactive bladder | beta-adrenoceptor
Journal Article
Trends in Pharmacological Sciences, ISSN 0165-6147, 2011, Volume 33, Issue 1, pp. 17 - 27
Journal Article
EUROPEAN UROLOGY, ISSN 0302-2838, 02/2016, Volume 69, Issue 2, pp. 311 - 323
Context: Mirabegron, the first beta(3)-adrenoceptor agonist in clinical practice, is approved for treatment of overactive bladder (OAB) syndrome symptoms.... 
PLACEBO | EFFICACY | Cardiovascular | MIRABEGRON | beta-Adrenoceptor agonist | BETA-ADRENOCEPTORS | 3-ADRENOCEPTOR AGONIST | PHARMACOKINETICS | URINARY-TRACT SYMPTOMS | IN-VIVO | DOUBLE-BLIND | UROLOGY & NEPHROLOGY | Overactive bladder | RITOBEGRON KUC-7483 | Safety
Journal Article
AGE AND AGEING, ISSN 0002-0729, 09/2014, Volume 43, Issue 5, pp. 666 - 675
Introduction: mirabegron is a beta(3)-adrenoceptor agonist developed for the treatment of symptoms of overactive bladder (OAB). As the prevalence of OAB... 
BETA-ADRENOCEPTOR AGONIST | DARIFENACIN | POPULATION | SAFETY | TOLTERODINE | ANTIMUSCARINIC AGENTS | COGNITIVE IMPAIRMENT | mirabegron | efficacy | GERIATRICS & GERONTOLOGY | tolerability | DOUBLE-BLIND | POOLED ANALYSIS | FESOTERODINE | older people | overactive bladder | age
Journal Article
Nature, ISSN 0028-0836, 03/2013, Volume 495, Issue 7442, pp. 534 - 538
Journal Article
EUROPEAN UROLOGY, ISSN 0302-2838, 01/2015, Volume 67, Issue 1, pp. 11 - 14
The beta(3)-adrenoceptor agonist mirabegron is approved for treatment of the symptoms of overactive bladder (OAB). Incontinence can be the most bothersome of... 
DETRUSOR | URGENCY | Correlation analysis | UROLOGY & NEPHROLOGY | Efficacy | Incontinence | Overactive bladder | BETA-ADRENOCEPTOR | Severity | Mirabegron
Journal Article
by Ge, XY and Woo, AYH and Xing, G and Lu, YL and Mo, YM and Zhao, Y and Lan, Y and Li, JY and Yan, HN and Pan, L and Zhang, YY and Lin, B and Cheng, MS
EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, ISSN 0223-5234, 05/2018, Volume 152, pp. 424 - 435
A new series of beta(2)-adrenoceptor agonists bearing the 2-amino-2-phenylethanol scaffold was synthesized. Evaluation of the compounds using cell assays and... 
DESIGN | CHEMISTRY, MEDICINAL | OLODATEROL | DISEASE | Bronchodilators | ASTHMA | Indacaterol | Trantinterol | beta-Adrenoceptor agonists | DISCOVERY | COPD
Journal Article
BRITISH JOURNAL OF PHARMACOLOGY, ISSN 0007-1188, 07/2010, Volume 160, Issue 5, pp. 1048 - 1061
Background and purpose: There are two important properties of receptor-ligand interactions: affinity (the ability of the ligand to bind to the receptor) and... 
subtype selectivity | ACTIVATION | beta-blocker | SUBTYPES | HUMAN BETA-ADRENOCEPTOR | PROTEIN-COUPLED RECEPTORS | GUINEA-PIG | cAMP | beta-adrenoceptor | efficacy | beta-antagonist | BLOCKERS | AFFINITY | whole-cell binding | intrinsic efficacy | GPCR | PHARMACOLOGY & PHARMACY | drug selectivity | PROVIDE EVIDENCE | beta-agonist
Journal Article
DIABETES, ISSN 0012-1797, 10/2018, Volume 67, Issue 10, pp. 2113 - 2125
beta 3-adrenergic receptor (AR) agonists are approved to treat only overactive bladder. However, rodent studies suggest that these drugs could have other... 
BETA-ADRENOCEPTOR AGONIST | OVERACTIVE BLADDER | ENERGY HOMEOSTASIS | ENDOCRINOLOGY & METABOLISM | MYOCARDIAL OXYGEN-CONSUMPTION | GENE-EXPRESSION | DOUBLE-BLIND | FUNCTIONAL-CHARACTERIZATION | ADULT HUMANS | COLD | BROWN FAT
Journal Article
No results were found for your search.

Cannot display more than 1000 results, please narrow the terms of your search.